Clinical audit on the management of acquired platelet disorders in Assiut University children hospital
Introduction Platelet disorders lead to defects in primary hemostasis and produce signs and symptoms different from coagulation factor deficiencies (disorders of secondary hemostasis). Primary hemostatic disorders are characterized by prolonged bleeding time and the characteristic physical examinati...
Gespeichert in:
Veröffentlicht in: | Journal of Current Medical Research and Practice 2017-09, Vol.2 (3), p.183-185 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction
Platelet disorders lead to defects in primary hemostasis and produce signs and symptoms
different from coagulation factor deficiencies (disorders of secondary hemostasis). Primary
hemostatic disorders are characterized by prolonged bleeding time and the characteristic
physical examination in the form of mucocutaneous bleeding. Initial laboratory evaluations for
patients with acquired platelet disorders include complete blood count and peripheral blood
smear. Treatment of patients with suspected acquired platelet disorder is generally specific
to the underlying disorder.
Patients and methods
Data of children older than 1 month of age admitted with bleeding tendency caused by acquired
platelet disorders during 1 year were collected and analyzed, and clinical management was
compared with the standard management guidelines according to the American Society of
Hematology 2011.
Results
In all patients, complete blood count was performed, whereas peripheral blood smear was
performed only for 46 (60.5%) cases. Bone marrow examination was performed in 30 (39.5%)
cases and it was indicated in 23 (77%) of these cases, whereas in seven (23%) cases it
was done for purpose of research with guardian consent. Medical treatment (in the form of
intravenous immunoglobulin and/or corticosteroids) was provided to seven (9%) cases in whom
treatment was not indicated. Intravenous immunoglobulin was administered to 22 (29%) cases,
and there was a delay in its administration to 10 (45%) of these cases because of unavailability.
Corticosteroids were administered to 26 (34%) cases; eight (31%) of these cases received it
for a longer time than indicated. Anti‑D immunoglobulin was not administered to any patient. |
---|---|
ISSN: | 2357-0121 2357-013X |
DOI: | 10.4103/JCMRP.JCMRP_16_17 |